The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats
Na Wu, Ying Wan, Lu Song, Chen Qi, Zhenguo Liu, Jing Gan Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China Background: Levodopa-induced dyskinesia (LID) is a troublesome problem in the treatment of Parkinson’s disease (PD)....
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ed7204c271b74e0891204c9a11363bac |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ed7204c271b74e0891204c9a11363bac |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ed7204c271b74e0891204c9a11363bac2021-12-02T01:15:53ZThe abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats1178-2021https://doaj.org/article/ed7204c271b74e0891204c9a11363bac2018-07-01T00:00:00Zhttps://www.dovepress.com/the-abnormal-activation-of-d1rshp-2-complex-involved-in-levodopa-induc-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Na Wu, Ying Wan, Lu Song, Chen Qi, Zhenguo Liu, Jing Gan Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China Background: Levodopa-induced dyskinesia (LID) is a troublesome problem in the treatment of Parkinson’s disease (PD). The mechanisms of LID are still mysterious. Recently, the interaction between Shp-2 and D1 dopamine receptor (D1R) has been identified to be indispensable in the D1R-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation and the occurrence of LID. However, the role of Shp-2 in the D1R-mediated signaling pathway of dyskinetic rat models is not fully clear. We designed this study with the purpose of exploring the role of D1R/Shp-2 complex in the D1R-mediated signaling pathway in the occurrence of LID.Materials and methods: The 6-hydroxydopamine (6-OHDA) was injected unilaterally to produce the rat models of PD. Successful PD rat models were randomly divided into three groups to receive the treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) + benserazide, L-DOPA + benserazide + D1R antagonist (SCH23390) or D1R agonist (SKF38393). Abnormal involuntary movements were assessed in different groups during the treatment. The interaction between D1R and Shp-2 was confirmed in the sham and LID rats through the methods of coimmunoprecipitation. In addition, the levels of p-Shp-2, p-ERK1/2 and p-mTOR were determined by Western blot in different groups.Results: After the treatment with L-DOPA + benserazide for 22 days, PD rats presented with dyskinesia. D1R agonist, SKF38393, induced similar involuntary movements in PD rats. In contrast, the dyskinetic movements were not induced by coadministration of L-DOPA + D1R antagonist (SCH23390). The interaction between D1R and Shp-2 in the normal rats was kept stable after the long-term use of L-DOPA. Moreover, we found that the pulsatile levodopa administration induced hyperphosphorylation of Shp-2, ERK1/2 and mTOR, while the coadministration of L-DOPA and D1R antagonist, SCH23390, did not induce the hyperphosphorylation of these proteins.Conclusion: These data verified the existence of D1R/Shp-2 complex and its crucial role in the D1R-mediated signaling pathway in dyskinetic rats. Focus on the D1R/Shp-2 complex might be a potential treatment of LID in the future. Keywords: Parkinson’s disease, dyskinesia, levodopa, D1 receptors, Shp-2Wu NWan YSong LQi CLiu ZGan JDove Medical PressarticleParkinson’s diseaseDyskinesialevodopaD1 receptorsShp-2.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 14, Pp 1779-1786 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Parkinson’s disease Dyskinesia levodopa D1 receptors Shp-2. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Parkinson’s disease Dyskinesia levodopa D1 receptors Shp-2. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wu N Wan Y Song L Qi C Liu Z Gan J The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats |
| description |
Na Wu, Ying Wan, Lu Song, Chen Qi, Zhenguo Liu, Jing Gan Department of Neurology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China Background: Levodopa-induced dyskinesia (LID) is a troublesome problem in the treatment of Parkinson’s disease (PD). The mechanisms of LID are still mysterious. Recently, the interaction between Shp-2 and D1 dopamine receptor (D1R) has been identified to be indispensable in the D1R-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation and the occurrence of LID. However, the role of Shp-2 in the D1R-mediated signaling pathway of dyskinetic rat models is not fully clear. We designed this study with the purpose of exploring the role of D1R/Shp-2 complex in the D1R-mediated signaling pathway in the occurrence of LID.Materials and methods: The 6-hydroxydopamine (6-OHDA) was injected unilaterally to produce the rat models of PD. Successful PD rat models were randomly divided into three groups to receive the treatment with L-3,4-dihydroxyphenylalanine (L-DOPA) + benserazide, L-DOPA + benserazide + D1R antagonist (SCH23390) or D1R agonist (SKF38393). Abnormal involuntary movements were assessed in different groups during the treatment. The interaction between D1R and Shp-2 was confirmed in the sham and LID rats through the methods of coimmunoprecipitation. In addition, the levels of p-Shp-2, p-ERK1/2 and p-mTOR were determined by Western blot in different groups.Results: After the treatment with L-DOPA + benserazide for 22 days, PD rats presented with dyskinesia. D1R agonist, SKF38393, induced similar involuntary movements in PD rats. In contrast, the dyskinetic movements were not induced by coadministration of L-DOPA + D1R antagonist (SCH23390). The interaction between D1R and Shp-2 in the normal rats was kept stable after the long-term use of L-DOPA. Moreover, we found that the pulsatile levodopa administration induced hyperphosphorylation of Shp-2, ERK1/2 and mTOR, while the coadministration of L-DOPA and D1R antagonist, SCH23390, did not induce the hyperphosphorylation of these proteins.Conclusion: These data verified the existence of D1R/Shp-2 complex and its crucial role in the D1R-mediated signaling pathway in dyskinetic rats. Focus on the D1R/Shp-2 complex might be a potential treatment of LID in the future. Keywords: Parkinson’s disease, dyskinesia, levodopa, D1 receptors, Shp-2 |
| format |
article |
| author |
Wu N Wan Y Song L Qi C Liu Z Gan J |
| author_facet |
Wu N Wan Y Song L Qi C Liu Z Gan J |
| author_sort |
Wu N |
| title |
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats |
| title_short |
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats |
| title_full |
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats |
| title_fullStr |
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats |
| title_full_unstemmed |
The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson’s rats |
| title_sort |
abnormal activation of d1r/shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned parkinson’s rats |
| publisher |
Dove Medical Press |
| publishDate |
2018 |
| url |
https://doaj.org/article/ed7204c271b74e0891204c9a11363bac |
| work_keys_str_mv |
AT wun theabnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT wany theabnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT songl theabnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT qic theabnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT liuz theabnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT ganj theabnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT wun abnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT wany abnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT songl abnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT qic abnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT liuz abnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats AT ganj abnormalactivationofd1rshp2complexinvolvedinlevodopainduceddyskinesiain6hydroxydopaminelesionedparkinsonrsquosrats |
| _version_ |
1718403231051153408 |